Polymorphism of Organic Cation Transporter 2 Improves Glucose-Lowering Effect of Metformin via Influencing Its Pharmacokinetics in Chinese Type 2 Diabetic Patients

Molecular Diagnosis and Therapy

Volumn 19, Issue 1, 2015, Pages 25-33

  Hou, Wolin ^a   Zhang, Dandan ^a   Lu, Wei ^a   Zheng, Taishan ^a   Wan, Lili ^a   Li, Qing ^a   Bao, Yuqian ^a   Liu, Fang ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; HEMOGLOBIN A1C; METFORMIN; ORGANIC CATION TRANSPORTER 2; URIC ACID; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; ORGANIC CATION TRANSPORTER; SLC22A2 PROTEIN, HUMAN;

ADULT; AGE; AGED; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; ELIMINATION HALF-LIFE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; URINARY EXCRETION; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; GENETICS; HETEROZYGOTE; KIDNEY; METABOLISM; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; HEMOGLOBIN A, GLYCOSYLATED; HETEROZYGOTE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; METFORMIN; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 84925536666     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-014-0126-z     Document Type: Article

References (23)

1. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25–33.
2. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, Ramirez AH, Roden DM, Wilke RA, McCarty CA, Davis RL, Brett CM, Giacomini KM. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93:186–94.
3. Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res. 2002;19(8):1244–7.
4. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20(5):379–86.
5. Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K. A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenetics Genomics. 2013;23(10):526–34.
6. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17(10):1100–9.
7. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenetics Genomics. 2008;18(7):637–45.
8. Chen Y, Li S, Brown C, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenetics Genomics. 2009;19(7):497–504.
9. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Clark AG, Herskowitz I, Giacomini KM. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12(5):395–405.
10. Fukushima-Uesaka H, Maekawa K, Ozawa S, Komamura K, Ueno K, Shibakawa M, Kamakura S, Kitakaze M, Tomoike H, Saito Y, Sawada J. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet. 2004;19(3):239–44.
11. Ogasawara K, Terada T, Motohashi H, Asaka J, Aoki M, Katsura T, Kamba T, Ogawa O, Inui K. Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet. 2008;53(7):607–14.
12. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics. 2008;9(4):415–22.
13. Li Q, Liu F, Zheng TS, Tang JL, Lu HJ, Jia WP. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol Sin. 2010;31(2):184–90.
14. Cheng CL, Chou CH. Determination of metformin in human plasma by high-performance liquid chromatography with spectrophotometric detection. J Chromatogr B Biomed Sci Appl. 2001;762(1):51–8.
15. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359–71.
16. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med. 2007;24(4):350–8.
17. Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics. 2003;13(9):581–4.
18. Yin OQ, Tomlinson B, Chow MS. Variability in renal clearance of substrates for renal transporters in chinese subjects. J Clin Pharmacol. 2006;46(2):157–63.
19. Yoon H, Cho HY, Yoo HD, Kim SM, Lee YB. Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects. AAPS J. 2013;15(2):571–80.
20. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, Shin JG. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84(5):559–62.
21. Zolk O, Solbach TF, Konig J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p. 270Ala > Ser. Drug Metab Dispos. 2009;37(6):1312–8.
22. Van Leeuwen N, Nijpels G, Dekker JM, Welschen L, Thart LM. The effect of genetic variation in OCT1, OCT2 and MATE1 on metformin treatment response. Diabetes. 2011;60:A387.
23. Tkáč I, Klimčáková L, Javorský M, Fabianová M, Schroner Z, Hermanová H, Babjaková E, Tkáčová R. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab. 2013;15(2):189–91.